Experts warn of deaths linked to Neurocrine's Vykat XR for Prader-Willi syndrome

A coalition of specialists in Prader-Willi syndrome has raised serious concerns about the safety profile of Neurocrine Biosciences' drug Vykat XR.

The experts point to a series of adverse events, including seven reported deaths that appear to be connected to the medication, along with other serious side effects.

In response, Neurocrine has issued new safety warnings and regulators are reviewing the data to determine whether additional actions are required.

The developments could affect treatment options for patients with Prader-Willi syndrome and may influence investor sentiment toward Neurocrine.